Brexucabtagene Autoleucel versus Allogeneic Hematopoietic Cell Transplantation in Relapsed and Refractory Mantle Cell Lymphoma

20256 citationsJournal Articlegreen Open Access

Authors

Nora Liebers · Heidelberg University

Ariane Boumendil · Sorbonne Université

Hervé Finel · European Society for Blood and Marrow Transplantation

Dominic Edelmann · German Cancer Research Center

Guido Kobbe · Düsseldorf University Hospital

Ben‐Niklas Baermann · Düsseldorf University Hospital

Yasmina Serroukh

Abstract

Patients aged ≥50 years with r/r MCL had superior OS and lower nonrelapse mortality 1 year after receiving brexu-cel compared with alloHCT. However, the long-term PFS and OS are similar for both treatments. Individual risk-benefit evaluation is essential to guide optimal treatment decisions.

Topics & Keywords

Lymphoma Diagnosis and Treatment Vascular Tumors and Angiosarcomas Sarcoma Diagnosis and Treatment

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Blood Cancer Discovery

Volume 6, Issue 3, pp. 182-190

DOI: 10.1158/2643-3230.bcd-24-0178

Field-Weighted Citation Impact: 8.85